Rigel Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND SHORT-TERM INVESTMENTS (Tables)

6 Months Ended

Jun. 30, 2025

Cash, cash equivalents, restricted cash, and short-term investments for the periods presented consist of the following (in thousands):


	As of
	June 30, 2025		December 31, 2024
Cash	$	17,614	$	20,135
Restricted cash		57		—
Money market funds		17,166		16,386
US treasury bills		32,294		7,263
Government-sponsored enterprise securities		9,973		23,177
Corporate bonds and commercial paper		31,332		10,360
	$	108,436	$	77,321
Reported as:
Cash and cash equivalents	$	53,407	$	56,746
Short-term investments		54,972		20,575
Restricted cash reported within other assets		57		—
	$	108,436	$	77,321

Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of June 30, 2025	Cost		Gains		Losses		Fair Value
US treasury bills	$	32,285	$	11	$	(2)	$	32,294
Government-sponsored enterprise securities		9,970		5		(2)		9,973
Corporate bonds and commercial paper		31,338		3		(9)		31,332
Total	$	73,593	$	19	$	(13)	$	73,599


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of December 31, 2024	Cost		Gains		Losses		Fair Value
US treasury bills	$	7,260	$	3	$	—	$	7,263
Government-sponsored enterprise securities		23,174		3		—		23,177
Corporate bonds and commercial paper		10,356		4		—		10,360
Total	$	40,790	$	10	$	—	$	40,800


As of June 30, 2025	Fair Value		Gross Unrealized Losses
US treasury bills	$	11,130	$	(2)
Government-sponsored enterprise securities		5,938		(2)
Corporate bonds and commercial paper		26,353		(9)
Total	$	43,421	$	(13)